Beijing Yimiao Medical Technology

Beijing Yimiao Shenzhou Medical Technology is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of chimeric antigen receptor T-cell (CAR-T) therapies. The company has established a comprehensive technology platform that integrates gene vector construction, cell process development, and large-scale GMP manufacturing. Its lead product candidate, IM19, is a CD19-targeted CAR-T therapy currently in registrational clinical trials for B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma. Beyond oncology, Yimiao Shenzhou is expanding its pipeline into autoimmune diseases, including systemic lupus erythematosus. The company distinguishes itself through its proprietary non-viral gene delivery systems and automated manufacturing processes designed to improve the safety and accessibility of cell therapies.